Table 2.

Summary of safety events

	Esaxerenone (n = 51)
At least one AE, n (%)	25 (49.0)
TEAEs reported in ≥3% of patients, n (%)
Viral upper respiratory tract infection	10 (19.6)
Increased serum K+	6 (11.8)
Back pain	2 (3.9)
At least one drug-related AE, n (%)	4 (7.8)
Thrombotic cerebral infarction	1 (2.0)
Increased serum K+	3 (5.9)
Treatment discontinued due to an AE, n (%)	2 (3.9)
Thrombotic cerebral infarction	1 (2.0)
Rash generalized	1 (2.0)
Discontinuation due to increased serum K+	0 (0)
Dose reduction due to serum K+ ≥5.5 to <6.0 mEq/L on two consecutive measurements, n (%)	1 (2.0)

AE adverse event, TEAE treatment-emergent adverse event